Adageis to Launch Series A Funding Round, Seeking $10M in Growth Capital

• Adageis is opening a Series A funding round, capital raise, aiming to raise $10 million for growth and expansion.
• The company previously closed a $2 million seed round in Q4 2024 to enhance operations and market reach.
• Adageis expects to exceed growth targets for Q1 2025, with strong market adoption of its AI-powered platform designed to streamline healthcare operations, optimize revenue, and improve patient care outcomes.
• The company has cut onboarding time from four weeks to one week, accelerating customer acquisition and revenue growth.

Adageis, a healthcare technology company reshaping patient care through flexible AI-centric software solutions for healthcare organizations, is launching a Series A funding round to raise $10 million in growth capital. This follows the company’s successful $2 million seed round at the end of Q4 2024, which supported backend improvements, expanded electronic health record (“EHR”) connectivity, and an increased sales force.

The company is targeting a total of $20 million in funding to fuel its next phase of growth, with a minimum investment of $250,000 required to participate. The capital will be allocated as follows:

• 40%: Expansion of SaaS platform team
• 45%: Development of a healthcare factoring division
• 15%: Technology upgrades to support fintech AI transition

Adageis is positioning itself as a key player in healthcare financial technology, helping providers optimize revenue and streamline operations. Representing the only offering of its kind in the healthcare sector, the company’s AI-powered ProActive Care Platform enables providers a more effective way to transition from traditional fee-for-service models to value-based care, improving both patient outcomes and financial performance.

The company’s Patented Risk Engine (“PRE”) enables predictive analytics for revenue performance, identifying patterns in patient care and financial incentives. Key financial benefits include:

• Cash Flow Management: AI can predict revenue performance from quality incentives, enabling providers to factor accounts receivables for pay-per-performance payments.
• Debt Leverage: Healthcare professionals can use AI-driven insights to access funding for operations and expansion, aggregating payments from insurance companies, ACOs, IPAs, and CINs.

Adageis’ fintech AI solutions are designed to simplify the complexities of insurance contracts, making it easier for providers to maximize reimbursements. By seamlessly integrating with widely used platforms like AthenaHealth, Cerner, eClinicalWorks, Allscripts, and Epic, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care revenue optimization.

The company expects to exceed its Q1 2025 growth targets, highlighting market demand for its services. Up to date, the company reports 150,000 patient lives currently covered, 70 providers across two states using the platform, one awarded patent from the USPTO, integration with over 90 EHR systems and up to $75,000 per provider in additional value-based care revenue.

By the end of Q2 2025, Adageis anticipates:

• 580,000 patient lives covered
• $100,000 in monthly recurring revenue
• Two to three new clients onboarded per month

To support this expansion, the company has streamlined its onboarding process, reducing implementation time from four weeks to just one week.

With its upcoming Series A funding round, Adageis is positioning itself for significant expansion in the healthcare technology space, offering investors an opportunity to support a rapidly growing company in the evolving $19.27 billion healthcare AI market.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN